©Zhiguo He
Théa Open Innovation signs an exclusive Licensing Agreement for the rights on Ripple Therapeutics Corporation lead product, IBE-814 for North America and Europe.
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases.
Feel free to contact us to submit your project or ideas.
Théa Open Innovation
12 rue Louis-Blériot
63017 CLERMONT-FERRAND cedex
FRANCE
Tel. +33 (0)4 73 98 14 36
© Théa Open Innovation 2024 | Personal data protection | Terms & conditions | Legal terms | Site Map